LONDON, August 07, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 13.03% on an annualized basis producing an ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

VERTEX PHARMACEUTICALS INCORPORATED (VRTX) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 94% based on the firm’s underlying fundamentals ...

Trading Advice for Vertex Pharmaceuticals Incorporated VRTX including day trading swing trading and long term investing plans for VRTX ...

Investors should also note that VRTX has a PEG ratio of 837.5 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.79% higher to $477.90 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 ...

Vertex Pharmaceuticals Incorporated (VRTX) stock saw a modest uptick, ending the day at $485.37 which represents a slight increase of $6.72 or 1.40% from the prior close of $478.65. The stock opened ...